Actively Recruiting
Patient-Reported Health Status Assessment Using the KCCQ for Early Detection of Heart Failure Worsening
Led by I.M. Sechenov First Moscow State Medical University · Updated on 2026-04-27
120
Participants Needed
1
Research Sites
130 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This observational feasibility study aims to assess (i) how practical and acceptable repeated KCCQ assessments are; (ii) the connection between changes over time in KCCQ scores and signs of congestion; and (iii) clinical outcomes, including worsening heart failure events or cardiovascular death (CVD), and the time between 5- and 10-point KCCQ changes and clinical events.
CONDITIONS
Official Title
Patient-Reported Health Status Assessment Using the KCCQ for Early Detection of Heart Failure Worsening
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Established diagnosis of chronic heart failure with reduced, mildly reduced, or preserved ejection fraction, NYHA class II-III
- History of heart failure hospitalization within the last 6 months, including symptoms such as dyspnea, elevated NT-proBNP levels, and signs of congestion
- Free of signs and symptoms of congestion, including low jugular venous pressure, no orthopnea, no pulmonary rales, and minimal or no peripheral edema
- Stable doses of oral loop diuretics if prescribed
- Ability to provide informed consent
You will not qualify if you...
- Recent acute coronary syndrome, cardiac surgery, pulmonary embolism, cerebrovascular accident, or atrial flutter/fibrillation ablation within the last 3 months
- Planned major cardiac interventions or device implantations during the study period
- Previous heart transplantation or candidacy for heart transplantation
- Complex congenital heart disease
- Heart failure caused by active myocarditis, pericardial constriction, hypertrophic cardiomyopathy, cardiac amyloidosis, or uncorrected severe valvular heart disease
- Primary pulmonary hypertension, chronic pulmonary embolism, or severe pulmonary disease
- Severe liver disease such as cirrhosis or chronic active hepatitis
- Significant drug or alcohol abuse within the last year
- Receiving hemodialysis
- Infective endocarditis
- Any active cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Moscow, Non-US/Non-Canadian, Russia
Actively Recruiting
Research Team
A
Anastasia Shchendrygina
CONTACT
S
Svetlana Rachina
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here